CTY Stock Chart & Stats
21.46
-0.94(-4.20%)
―
--
Day’s Range― - ―
52-Week Range20.50 - 23.88
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.41M
Market Cap
$1.08B
Enterprise ValueN/A
Total Cash (Recent Filing)$5.00M
Total Debt (Recent Filing)$4.66B
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding50,332,280
10 Day Avg. Volume1,406,423
30 Day Avg. Volume1,406,423
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.03
P/FCF Ratio0.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CTY FAQ
What was City Therapeutics, Inc.’s price range in the past 12 months?
City Therapeutics, Inc. lowest stock price was 20.50 and its highest was 23.88 in the past 12 months.
What is City Therapeutics, Inc.’s market cap?
City Therapeutics, Inc.’s market cap is $1.08B.
When is City Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were City Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is City Therapeutics, Inc. overvalued?
According to Wall Street analysts City Therapeutics, Inc.’s price is currently Undervalued.
Does City Therapeutics, Inc. pay dividends?
City Therapeutics, Inc. does not currently pay dividends.
What is City Therapeutics, Inc.’s EPS estimate?
City Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does City Therapeutics, Inc. have?
City Therapeutics, Inc. has 50,332,280 shares outstanding.
What happened to City Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of City Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CTY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
City Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth $6.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
18.28%
Trailing 12-Months
Asset Growth
―
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
City Therapeutics, Inc.
City Therapeutics, Inc. is a biotechnology company specializing in next-generation RNA interference (RNAi) therapeutics. The company is based in Cambridge, MA. The company engineers potent, specific, and durable RNAi trigger molecules combined with precision targeting ligands to deliver siRNAs beyond the liver to tissues such as ocular and central nervous system targets. Its R&D pipeline includes programs addressing thromboembolic diseases (targeting Factor XI), Stargardt disease (targeting RBP4), and other hepatic, ocular, and CNS conditions. Lead candidates include CITY-FXI, designed to prevent blood clots with reduced bleeding risk, and CITY-RBP4, aimed at slowing or halting vision loss in Stargardt disease. The company was founded by Ari Nowacek, John M. Maraganore. Andrew C. Orth has been the CEO of the company since 2025.
Arbutus Biopharma
―
Wave Life Sciences
―
Editas Medicine
―
Stoke Therapeutics
―
Silence Therapeutics
―
Ownership Overview
58.60% Insiders
―
Mutual Funds
― Other Institutional Investors
41.40% Public Companies and
Individual Investors